Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Pfenex And Hospira Join On Biosimilars
by Ann M. Thayer
February 16, 2015
| A version of this story appeared in
Volume 93, Issue 7
Pfenex, a San Diego-based biotech firm, will work with the generic drug firm Hospira to develop a biosimilar version of Genentech’s eye drug Lucentis. In 2014, sales of Lucentis were about $4 billion. Hospira will pay Pfenex $51 million up front and up to $291 million more in milestone payments. Pfenex’s PF582 monoclonal antibody is in clinical trials to assess its safety and tolerability, and to compare its pharmacokinetics and pharmacodynamics to Lucentis. Pfizer is in the process of acquiring Hospira in a $17 billion deal.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter